Lead Sponsor

Janssen Research & Development, LLC

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Participants must have Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
•Participants must have cardiac parameters within the following range: corrected QT interval (QTcF) less than or equal to \<= 480 milliseconds based on the average of triplicate assessments performed as close as possible in succession (the full set of triplicates should be completed in less than 10 minutes)
•Women of childbearing potential must have a negative highly sensitive serum pregnancy test (example: beta human chorionic gonadotropin \[beta-hCG\]) at screening, and a negative serum or urine pregnancy test prior to the first dose of study drug
•Women must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of at least 30 days after the last study drug administration
•Participants must be willing and able to adhere to the lifestyle restrictions specified in this protocol

•Participant has known active central nervous system (CNS) involvement
•Participant has received prior solid organ transplantation
•Participant has known allergies, hypersensitivity, or intolerance to JNJ-64264681 or its excipients
•Participant has been treated with an investigational drug (including investigational vaccines) within five half-lives or 2 weeks before the planned first dose of study drug
•Participant is experiencing toxicities from previous anticancer therapies that have not resolved to baseline levels, or to Grade 1 or less (except for alopecia and peripheral neuropathy)

Related studies

NCT06510361 · Lymphoma, Follicular Lymphoma, and more

NCT05442515 · B-NHL, B-Non Hodgkin Lymphoma, and more

NCT07162181 · Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, and more

NCT06528301 · Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), and more

NCT05824585 · Lymphoma, Non-Hodgkin

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia